Newsroom | 9400 results

Sorted by: Latest

Cardiology
-

VahatiCor Appoints Harry D. Rowland, Ph.D., as Chief Executive Officer

SANTA CLARA, Calif.--(BUSINESS WIRE)--VahatiCor, Inc., a medtech company developing interventional therapies for Coronary Microvascular Dysfunction (CMD), announced today the appointment of Harry D. Rowland, Ph.D., as Chief Executive Officer. Rowland previously served as Chief Executive Officer and President of Endotronix, where he led the development and commercialization of the Cordella™ Pulmonary Artery Sensor and Heart Failure System. Under his leadership, Endotronix raised over $150 millio...
-

Tulyp Medical Appoints Industry Veteran Steve Motes as CEO to Lead Next Phase of Growth in the US

PARIS & DALLAS--(BUSINESS WIRE)--Tulyp Medical, a Paris-based medical device company developing an intelligent pressure-driven perfusion system, today announced the appointment of Steve Motes as Chief Executive Officer. The appointment follows positive results from the company’s first-in-human study. Steve joins Tulyp with more than 30 years of experience in the medical device industry, primarily focused on cardiovascular technologies. He has held leadership roles at Draeger, Medtronic (formerl...
-

United Therapeutics Corporation Announces ADVANCE OUTCOMES Study of Ralinepag Presented at ATS 2026

SILVER SPRING, Md. & RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--United Therapeutics Corporation (Nasdaq: UTHR), a public benefit corporation, today announced that full results of its ADVANCE OUTCOMES study are being presented today during the Breaking News: 2026 Clinical Trial Results in Pulmonary Medicine session at the annual meeting of the American Thoracic Society (ATS) International Conference in Orlando. Ralinepag has not been approved for use in any indication by the U.S. Food and Dr...
-

United Therapeutics Corporation Announces FDA Clearance to Proceed with UHeart Xenotransplantation Clinical Trial

SILVER SPRING, Md. & RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--United Therapeutics Corporation (Nasdaq: UTHR), a public benefit corporation, today announced that the U.S. Food and Drug Administration (FDA) has granted clearance under the company’s Investigational New Drug application to proceed with a clinical study of its investigational UHeart™ derived from a pig with 10 gene edits. The study, known as EXPRESS, will enroll an initial cohort of up to two participants. United Therapeutics...
-

Teleflex Announces Quarterly Dividend

WAYNE, Pa.--(BUSINESS WIRE)--Teleflex Incorporated (NYSE: TFX) announced today that its Board of Directors declared a quarterly cash dividend of thirty-four cents ($0.34) per share of common stock. The dividend is payable June 30, 2026, to shareholders of record at the close of business on May 25, 2026. About Teleflex Incorporated As a global provider of medical technologies, Teleflex is driven by our purpose to improve the health and quality of people’s lives. Through our vision to become the...
-

ICUS Commends New Proposal Supporting CEUS Training for Sonographers

CHICAGO--(BUSINESS WIRE)--New standards proposed by CAAHEP will require students at accredited sonography training programs to demonstrate knowledge of CEUS....
-

Secretome Therapeutics Announces Participation in Upcoming Summer Investor Conferences

PLANO, Texas--(BUSINESS WIRE)--Secretome Therapeutics, a clinical-stage biotechnology company developing novel cellular and cell-based therapies derived from neonatal cardiac progenitor cells (nCPCs), today announced that members of its management team will participate in three upcoming investor conferences this summer. Secretome is scheduled to attend the following conferences: Jefferies Global Healthcare Conference June 2 – 4, 2026 New York, New York Oppenheimer CNS & Neuro-Muscular Summi...
-

Iterative Health Acquires Cardiology Sites from NextStage Clinical Research

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Iterative Health announced the acquisition of three cardiology sites from NextStage Clinical Research....
-

Covalon Announces Conference Call to Discuss Second Quarter Fiscal 2026 Results

MISSISSAUGA, Ontario--(BUSINESS WIRE)--Covalon Technologies Ltd. (the "Company" or "Covalon") (TSXV: COV; OTCQX: CVALF), an advanced medical technologies company, will release its Q2 Fiscal 2026 results on Thursday, May 21, 2026, before markets open. A conference call and webcast to discuss the results will be held on Thursday, May 21, 2026, at 8:30am ET. To view, listen to, and participate in the live webcast, please follow the link below: https://events.q4inc.com/attendee/485973962 To listen...
-

Ardent Health and Fujifilm Partner to Deliver Synapse Enterprise Imaging Across Radiology and Cardiology Throughout All Facilities

BRENTWOOD, Tenn. & LEXINGTON, Mass.--(BUSINESS WIRE)--Ardent Health (NYSE: ARDT), a leading provider of healthcare in growing mid-sized urban communities across the U.S., has partnered with FUJIFILM Healthcare Americas Corporation to implement its Synapse® enterprise imaging solutions across Ardent's acute care hospital footprint across six states. Fujifilm’s Synapse Enterprise Imaging solutions will provide Ardent clinicians with a single, holistic view of patient imaging data across various d...